Biotech: The Next Pricing Controversy?

Piper Jaffray’s Joshua Schimmer note that co-pay assistance programs that help patients afford expensive drugs and are used by companies like Amgen (AMGN), Biogen (BIIB),  Incyte (INCY), Celgene (CELG), and Gilead Sciences (GILD) are in the news once again–and that’s not necessarily a good thing.

Read more.

Related

JOIN THE DISCUSSION